Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Successor-1: Mezigdomide + bortezomib + dexamethasone vs pomalidomide + bortezomib + dexamethasone in RRMM
2023-509859-13-00Phase 3Authorised
- Sponsor
- Celgene Corporation
- Start
- Nov 2022
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of mezigdomide in multiple myeloma (MM) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free survival. Planned start Nov 2022; status: authorised.
02
Drugs
mezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-509859-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509859-13-00.